Athyrium Opportunities Fund III (AOF III)

Athyrium Opportunities Fund III1

Company Marketer / Counterparty Description Initial Investment Date
IMC Health IMC Health Multi-Specialty Provider Group February 2017
Alvogen Alvogen Specialty Generics April 2017
Teladoc Teladoc Telemedicine Platform July 2017
OB Hospitalist Group OB Hospitalist Group OB Hospitalist Services August 2017
DuPage Medical Group DuPage Medical Group Multi-Specialty Physician Group August 2017
Progenity, Inc. Progenity, Inc. Prenatal Women's Health Genetics and Gastrointestinal / Inflammatory Bowel Disease Precision Medicine October 2017
Recro Pharma Recro Pharma Post-Operative Pain / Contract Development and Manufacturing Organization November 2017
PharMerica PharMerica Institutional and Specialty Pharmacy Services Provider December 2017
Centinel Spine Centinel Spine Spine Total Disc Replacement and Integrated Interbody Systems December 2017
OptiNose OptiNose XHANCE / Exhalation Delivery Systems (EDS) platform December 2017
Veloxis Veloxis Envarsus XR / MeltDose Technology February 2018
Biom'Up Biom'Up HEMOBLAST Bellows / Hemostatic Products February 2018
Water's Edge Management, LLC Water's Edge Dermatology Dermatology Provider Group May 2018

1. This table lists all investments made by the Athyrium Opportunities Fund III.